Börskollen - Aktier, fonder och ekonominyheter
Börskollen
Risken: Anthropics egna forskare: Över 10 procents risk att AI utplånar mänskligheten

Analyser av Stenocare

Kurs från TradingView
Visa mer ▼
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

STENOCARE: Time to Capitalize on STENOCARE 3.0 - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six ...

Analyst Group • 19 maj 2025 10:05

Analyst Group Comment on STENOCARE's Q1-report

STENOCARE A/S (STENOCARE or the “Company”) published on May 8th the Company’s Q1-report for 2025.

Analyst Group • 09 maj 2025 07:25

Analyst Group Comment on STENOCARE ASTRUM 10-10 Oil Being Approved for Reimbursement in Germany

On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for reimbursement in Germany through major heal...

Analyst Group • 04 apr 2025 09:20

STENOCARE: All Focus on Astrum - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six ...

Analyst Group • 06 mar 2025 14:17

Analyst Group's Comment on STENOCARE’s Q4-report Report 2024

STENOCARE A/S (STENOCARE or the “Company”) published on February 27th the Company’s Q4-report for 2024.

Analyst Group • 27 feb 2025 16:05

Analyst Group Comment on the Outcome of STENOCARE’s Conditional Rights Issue

On January 22nd, STENOCARE announced the outcome of the conditional rights issue, which was subscribed to approximately 37.

Analyst Group • 23 jan 2025 07:22

Analyst Group's Comment on STENOCARE’s Announcement of a Conditional Rights Issue of up to DKK 20.2m

On December 18th, STENOCARE announced that the company has resolved a rights issue of up to DKK 20.

Analyst Group • 20 dec 2024 11:36

Analyst Group Comment on Stenocare:s Approval for a new Medical Cannabis CBD100 oil - Analyst Group

On December 17th, STENOCARE announced that the company has received approval for a new product in Denmark, CBD100, which has a high concentr...

Analyst Group • 17 dec 2024 11:13

Analyst Group Comment on that STENOCARE’s Astrum Oil has been Approved for Sales in Norway

STENOCARE announced on December 2nd that the company’s premium product, the Astrum oil, has been approved for sales on the Norwegian market.

Analyst Group • 02 dec 2024 12:13

Analyst Group Comment on STENOCARE Shifting Strategy to Focus on Trading and Exit from Production

STENOCARE announced on November 26th the STENOCARE 3.

Analyst Group • 27 nov 2024 14:46

Comment on the Impact for Stenocare in Regards to the Danish Health Minister’s Decision to Propose a Permanent Legalization of Medical Cannabis - Analyst Group

Medical cannabis has been legal in Denmark under a pilot program since 2018 during a trial period that was set to expire in December 2025.

Analyst Group • 20 nov 2024 09:34

Stenocare: Tough Market Conditions Hampers the Growth - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) continues to experience tough market conditions in Denmark because of increased competition and...

Analyst Group • 11 nov 2024 15:07

Analyst Group Comment on STENOCARE’s Q3-Report 2024

STENOCARE published on November 5th the company’s Q3-report for 2024.

Analyst Group • 06 nov 2024 11:24

Analyst Group Comment on STENOCARE’s Updated Guidance for 2024

STENOCARE announced on October 14th that the company has updated the sales guidance for 2024, from gross sales of DKK 6-8m, which are now ex...

Analyst Group • 14 okt 2024 14:02

Stenocare: Delivers on Key Strategic Initiatives - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) has executed on several strategically important milestones during H1-24, including approval of ...

Analyst Group • 29 aug 2024 09:11

Analyst Group Comment on STENOCARE’s Q2-report Report 2024

STENOCARE published on August 21st the company’s Q2-report for 2024.

Analyst Group • 22 aug 2024 08:35

Analyst Group Comment on STENOCARE’s Expansion into Canada

STENOCARE announced on June 17th that the company is planning an expansion into Canada together with North America industry experts, which m...

Analyst Group • 17 jun 2024 15:16

Analyst Group kommenterar Stenocare

Med ett nytt godkännande i Danmark för en THC/CBD medicinsk cannabisolja har Stenocare återtagit positionen som enda leverantör av två av de...

Analyst Group • 12 jun 2024 14:43

Analyst Group's Comment on STENOCARE Launching Next Generation Medical Cannabis Oil Product in Australia

STENOCARE announced on May 23rd that the company’s premium product, the Astrum oil, is ready for launch on the Australian market.

Analyst Group • 23 maj 2024 16:11

STENOCARE: New Products Paves the way for Further Patient Growth - Analyst Group

With a new THC/CBD medical cannabis oil approved, which is ready for sales under the Danish pilot program, STENOCARE A/S (“STENOCARE” or the...

Analyst Group • 08 maj 2024 09:40

Analyst Group Comment on STENOCARE’s Q1-report Report 2024

STENOCARE published on May 2 the company’s Q1-report for 2024, showing progress.

Analyst Group • 02 maj 2024 12:12

Stenocare: An Exciting Year Ahead - Analyst Group

During 2023 STENOCARE delivered record in gross sales amounting to DKK 6.

Analyst Group • 01 mar 2024 08:35

Analyst Group's Comment on Stenocare's Q4-report

STENOCARE published on February 22nd its year-end report for 2023.

Analyst Group • 22 feb 2024 14:58

Analyst Group's Comment on STENOCARE Expanding in Australia

STENOCARE announced on December 14th that the company has entered into a new partnership agreement with Quest Biotech Pharma (“QBP”), aimed ...

Analyst Group • 15 dec 2023 07:15

Stenocare: Adding a new Product in Australia - Analyst Group

STENOCARE announced on November 23rd that the company has signed agreements that will make a new product, a Balanced 25-25 oil, available fo...

Analyst Group • 23 nov 2023 13:00

Stenocare: Strong Patient Growth in Denmark - Analyst Group

The number of patients continued to grow strongly during Q3-23 for STENOCARE A/S (“STENOCARE” or “the Company”) which resulted in actual sal...

Analyst Group • 14 nov 2023 11:19

Analyst Group Comment on STENOCARE’s Q3-Report 2023

STENOCARE published on November 9th its Q3-report for 2023.

Analyst Group • 10 nov 2023 07:37

Analyst Group Comment on STENOCARE’s Updated Guidance and One-off Return of Products from Norway

STENOCARE announced on November 6th an updated guidance for 2023 and 2024 as well as sales in Q3-23, amounting to DKK 2.

Analyst Group • 07 nov 2023 12:03

Analyst Group Comment on Stenocare’s Market Update

STENOCARE announced on September 18th a market update highlighting progress in several areas, including increased market share in Denmark, a...

Analyst Group • 19 sep 2023 10:41

Stenocare: Long-term Sales Drivers are Intact - Analyst Group

In Q2-23, STENOCARE delivered a sales growth of 279% Y-Y, amounting to DKK 1.

Analyst Group • 24 aug 2023 14:53

Comment on Stenocare’s Q2-report Report 2023

Stenocare published on August 17 its Q2-report for 2023.

Analyst Group • 17 aug 2023 15:06

Stenocare: Entering the Largest Market in Europe - Analyst Group

With the Q1-report presented, it is clear that STENOCARE A/S (“STENOCARE” or the “Company”), has laid the groundwork for future scale-up, fo...

Analyst Group • 28 jun 2023 12:11

Comment on Stenocare:s Q1-Report 2023 - Analyst Group

STENOCARE published on June 20 its Q1-report for 2023.

Analyst Group • 20 jun 2023 14:18

Analyst Group Comment on STENOCARE Launching an IT-platform for Online Clinics

STENOCARE announced on May 30th that the company has developed an IT-platform that enables doctors to launch and operate Online Clinics.

Analyst Group • 30 maj 2023 15:21

Analyst Group kommenterar STENOCAREs emission

STENOCARE genomför nu en företrädesemission fram till den 8 juni.

Analyst Group • 26 maj 2023 11:40

Analyst Group Comment on STENOCARE’s Product Approval in Germany

STENOCARE announced on May 25th, that a new medical cannabis oil product has received approval from the Federal Institute for Drugs and Medi...

Analyst Group • 25 maj 2023 12:45

Comments on STENOCARE'S Rights Issue - Analyst Group

On May 15, 2023, STENOCARE announced that the company intends to carry out a preferential Rights Issue of shares and warrants of series TO 1...

Analyst Group • 17 maj 2023 07:12

Stenocare: Capitalizing on the Growing Cannabis Market - Analyst Group

After entering three new markets in 2022, STENOCARE delivered products to a total of five countries during Q4-22, leading to net sales amoun...

Analyst Group • 02 mar 2023 09:39

Analyst Group comments on STENOCARE’s Year end Report 2022

STENOCARE published on February 23 its year end report for 2022.

Analyst Group • 23 feb 2023 13:45

Analyst Group Comment on STENOCARE’s Press Release Regarding Q4-22 Net Sales - Analyst Group

STENOCARE announced on Monday, January 9th, that products were delivered to its five markets during Q4-22, corresponding to net sales of DKK...

Analyst Group • 09 jan 2023 17:59

Stenocare: Initiate analys - Analyst Group

Analyst Group has entered into an agreement with STENOCARE on commissioned research, including e.

Analyst Group • 12 dec 2022 09:14